Up 64% in 6 months already; should you still buy Neogen Chemicals? Antique sees 23% upside potential - Check target

Antique Stock Broking initiated coverage on Neogen Chemicals with a Buy rating and a target price of Rs.3,050, implying a 23% upside. The brokerage expects strong earnings growth driven by battery chemicals, with revenue, EBITDA, and PAT growing at CAGRs of 45%, 49%, and 87% respectively from FY26 to FY30. The stock has surged 64% in 6 months but faces execution and debt management risks.

Original reporting
Published Oct 20, 2026, 7:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 8:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Up 64% in 6 months already; should you still buy Neogen Chemicals? Antique sees 23% upside potential - Check target — source image
Decision brief

The 30-second read

Med
01

Why it matters

The new coverage may attract short‑term buying pressure, but execution risk remains high.

02

Market read

Analyst initiation could spark interest in Neogen, but the story is confined to Indian markets.

03

What to watch

Possible delays in battery plant commissioning, debt servicing pressure, and regulatory changes in US tax‑credit rules.

Relevance 6/10Novelty 6/10Timing: today

Background

Antique Stock Broking initiates coverage on Neogen Chemicals with a Buy rating and a 23% upside target.

Market effects

Potential boost to Indian specialty chemicals and battery chemicals sector if Neogen executes growth plan.

May influence investor sentiment on Indian mid‑cap stocks, especially in chemicals and battery supply chain.

Limited; primarily a domestic Indian market story.

Counterpoint

The high valuation multiples and execution risks could outweigh upside, suggesting caution.

Key entities

  • Neogen Chemicals

    Indian specialty chemicals maker expanding into battery chemicals.

  • Antique Stock Broking

    Initiated coverage with a Buy rating and target price.

Related articles

Med

Neogen Chemicals Ltd (BOM:542665) (Q2 2027) Earnings Call Highlights: 42% Revenue

Neogen Chemicals (BOM:542665) reported Q2 2027 earnings, with a 42% revenue surge. The company guided FY27 battery chemicals revenue at INR 250-300 crore and FY28 at over INR 1,000 crore. Base chemicals guidance for FY27 was upgraded to over INR 1,100 crore. Net debt for FY28 is expected to be INR 1,300-1,500 crore. The company is benefiting from US demand shifts due to tax credits and has secured customer approvals for lithium electrolyte salts.

$NEOGHigh

Neogen Corporation announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc

NEOGEN CORP (NEOG) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On March 2, 2026, Neogen Corporation (“ Neogen ”) announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. (“ Zoetis ”). This transaction is subject to customary closing conditions and regulatory approva